Caribou Biosciences Target of Unusually Large Options Trading (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU) was the target of unusually large options trading on Monday. Stock traders acquired 2,867 call options on the stock. This is an increase of 726% compared to the average daily volume of 347 call options.

Institutional Trading of Caribou Biosciences

A number of hedge funds have recently bought and sold shares of the business. R Squared Ltd bought a new stake in Caribou Biosciences in the third quarter worth about $29,000. Liberty Wealth Management LLC bought a new position in Caribou Biosciences during the third quarter valued at $45,000. Next Capital Management LLC bought a new stake in shares of Caribou Biosciences in the second quarter valued at $25,000. Creative Planning purchased a new position in shares of Caribou Biosciences during the 2nd quarter valued at $25,000. Finally, Hudson Bay Capital Management LP bought a new stake in Caribou Biosciences in the 2nd quarter valued at about $30,000. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU traded down $0.16 during mid-day trading on Monday, hitting $1.79. The company had a trading volume of 494,782 shares, compared to its average volume of 1,583,665. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.54. The company has a market capitalization of $166.84 million, a PE ratio of -1.05 and a beta of 2.60. The firm has a fifty day moving average price of $2.25 and a 200 day moving average price of $1.83.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.The company had revenue of $2.20 million during the quarter, compared to the consensus estimate of $1.94 million. Research analysts expect that Caribou Biosciences will post -1.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRBU has been the topic of a number of recent analyst reports. Citigroup lifted their target price on Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, November 3rd. Wall Street Zen upgraded shares of Caribou Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 24th. HC Wainwright raised their target price on shares of Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Truist Financial set a $7.00 price target on Caribou Biosciences in a research note on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.75.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.